LifeNet Health Showcases Breakthrough MIS Technology at the 2022 NASS Annual Meeting


The exhibition presents ViviGen® MIS, the first viable cellular allograft delivery system designed specifically for minimally invasive surgery

CHICAGO, October 12, 2022 /PRNewswire/ — LifeNet Health Presents the Most Advanced Allograft Biologics for Fusion at the 2022 North American Spine Society (NASS) Annual Meeting in Chicago October 12-14 (Booth #3216). Global Leader in Allograft Solutions and Treatment Technology to Showcase the Growing Body of Evidence Supporting LifeNet Health’s Solutions for Thoracic, Cervical and Lumbar Fusions, Including ViviGen® Cellular Bone Matrix, PliaFX® Prime and VertiGraft Mouldable Demineralized Fibers® structural allografts.

LifeNet Health has tailored these solutions to overcome clinical challenges ranging from routine to the most complex fusions, including minimally invasive procedures. Visitors will have the exclusive opportunity to experience the speed and accuracy of ViviGen GIS delivery device in a carefully designed handling station. ViviGen MIS provides the clinical benefits of ViviGen in a device that makes graft delivery faster, more predictable and more precise. “It really meets all of our requirements to introduce the graft into the disc space quickly and efficiently,” said Deepak RedMD, of South Bend Orthopedics.

NASS participants can also experience the exceptional handling of PliaFX Premierthe most versatile osteobiological in the world, and the strength of VertiGraftwhose clinical performance has been demonstrated to be superior to PEEK spacers.

“Our vast data, cutting-edge technologies and best biologics are creating better lives,” said Rich Rice, LifeNet Health vice president for orthopedics and CMF. “We look forward to sharing with NASS clinicians how these solutions can bring unparalleled results to their patients and unparalleled efficiency to their procedures.”

Better data

NASS participants can explore peer-reviewed publications containing compelling data on the clinical effectiveness of LifeNet Health solutions. This includes published data showing that patients who received VertiGraft implants experienced significantly lower rates of non-union and reoperation than patients who received PEEK implants, as well as data that demonstrates how ViviGen supports positive outcomes even in complex multilevel fusions and in patients with comorbidities known to impair bone healing.

“We have good clinical data, we know it’s safe, and we’ve used it for years in so many patients and in so many applications,” Dr. Reddy said. “ViviGen in all of its formulations is a tool that surgeons can use to achieve a strong, robust fusion in a very patient-friendly and safe way.”

Best value

Throughout the exhibit, LifeNet Health will also highlight the unique combination of efficacy and economic value found in biologics such as PliaFX Prime and ViviGen. With no support to dilute its bone healing potential, PliaFX Prime’s all-cortical fiber design is based on data showing that all-bone grafts grow more bone than those with support.1.2 It also means that PliaFX Prime offers 100% value by delivering more bone volume than grafts that rely on a scaffold to improve handling.

Likewise, ViviGen Cellular Bone Matrix has been shown to not only deliver exceptional clinical results – with multilevel complex fusion rates of up to 98% – but also significantly lower hospital costs than other transplant solutions. A 2019 study showed that the fees associated with ViviGen were up to $50,000 lower than those associated with recombinant human bone morphogenetic protein-2 (rhBMP-2).3

For those unable to attend the show, these solutions are featured in the LifeNet Health digital showcase at

About LifeNet Health

LifeNet Health helps save lives, restore health and give hope to thousands of people every year. It is the world’s most trusted provider of transplant solutions – from organ procurement to bio-implants and cell therapies – and a leader in regenerative medicine, while always honoring donors and professionals of health that enable healing. For more information about LifeNet Health, visit

  1. Boyan BD, Ranly DM, McMillan J, et al. Osteoinductive capacity of human allograft formulations. J Periodontol. September 2006.
  2. Data from LifeNet Health TR-0446 record.
  3. Wetzell, B. McLean, JB, Moore, MA et al. A large database study of hospitalization costs and follow-up readmissions in lumbar fusion surgeries in the United States using cellular bone allograft (CBA) versus recombinant human bone morphogenetic protein-2 (rhBMP- 2). J Orthop Surg Res 15, 544 (2020).

SOURCELifeNet Health


Comments are closed.